Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Gomella on the Evolution of Genetic Testing in Prostate Cancer

May 7th 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of genetic testing in prostate cancer.

Dr. Cone on Research Investigating Cardiac Toxicity of GnRH Agonists/Antagonists in Prostate Cancer

May 7th 2020

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses research investigating the cardiac toxicity of gonadotropin-releasing hormone (GnRH) agonists and antagonists in prostate cancer.

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

May 7th 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Addition of Novel Hormonal Agents to Standard Therapy Explored in Node-Positive Prostate Cancer

May 6th 2020

Investigators are examining if the addition of apalutamide, abiraterone acetate, and prednisone to standard hormone and radiation therapy will be more effective than standard treatment alone in node-positive prostate cancer.

VERU-111 Shows Promise in mCRPC

May 5th 2020

VERU-111 demonstrated antitumor activity and durable PSA declines in men with metastatic castration-resistant prostate cancer who are resistant to at least 1 novel androgen-blocking agent.

Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate Cancer

May 5th 2020

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

Dr. Hwang on the Addition of Radium-223 to Abiraterone Acetate and Prednisone in mCRPC

May 5th 2020

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Tagawa Highlights Promise of Potent PSMA-Targeted Radionuclide Therapy in mCRPC

May 4th 2020

Scott T. Tagawa, MD, MS, FACP, provides background on radionuclide therapy, sheds light on the key findings from the trial, and discusses future directions with 225Ac-J591 in mCRPC.

MRI-Targeted and Systematic Biopsy Combo Enhances Diagnostic Accuracy in Prostate Cancer

May 1st 2020

The combination of MRI-targeted and systemic biopsy led to increased detection of all prostate cancers in patients with MRI-visible lesions.

Alternate Delivery Models for Genetic Counseling in Prostate Cancer

April 30th 2020

Alanna K. Rahm, PhD, MS, discusses alternate delivery models for genetic counseling in prostate cancer.

Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPC

April 30th 2020

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

Dr. Oh on Adapting the PRINT Trial Model to Other Settings in Prostate Cancer

April 30th 2020

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

April 30th 2020

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPC

April 30th 2020

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Dr. Chang on Efforts to Improve Quality of Life in Prostate Cancer

April 30th 2020

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Dr. Armstrong on the utility of PARP Inhibitors in Mutated Prostate Cancer

April 30th 2020

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Olaparib Pivotal mCRPC Data Published in NEJM as FDA Weighs Approval

April 29th 2020

Findings from the pivotal phase 3 PROfound trial of olaparib as a treatment for men with metastatic castration-resistant prostate cancer harboring homologous recombination repair (HRR) gene alterations were published in the New England Journal of Medicine.

Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer Management

April 29th 2020

Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.

Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPC

April 29th 2020

Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Beltran on the Limitations of Tissue Biopsies Versus Liquid Biopsies in CRPC-NE

April 29th 2020

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.